86 research outputs found
CD4+ CD52lo T細胞発現は全身性エリテマトーデスの病態形成に関与する
No full textThe cell-surface glycoprotein CD52 is widely expressed in lymphocytes. CD4+ CD52hi T cells are functioning suppressor CD4+ T cells. We investigated the role of the immune regulation of CD4+ CD52 T cells in systemic lupus erythematosus (SLE). CD4+ CD52lo T cells were increased in SLE patients, in positive correlation with SLEDAI, anti-ds-DNA antibody, and IgG concentration. Circulating follicular helper-like T cells (Tfh-like cells) were also increased in SLE, in positive correlation with CD4+ CD52lo T cells. Chemokine receptor 8 (CCR8) expression in CD4+ CD52lo T cells was increased. In vitro experiments using CD4 T cells of SLE patients showed that thymus and activation-regulated chemokine (TARC), a ligand of CCR8, contributed to the development of CD4+ CD52hi T cells into CD4+ CD52lo T cells. Our findings suggest that CD4 + CD52lo T-cell upregulation is involved in the production of pathogens by autoantibodies, and TARC may contribute to the development of SLE through an aberrant induction of CD4+ CD52lo T cells.長崎大学学位論文 学位記番号:博(医歯薬)甲第1044号 学位授与年月日:平成30年3月20日Author: Masataka Umeda, Tomohiro Koga, Kunihiro Ichinose, Takashi Igawa, Tomohito Sato, Ayuko Takatani, Toshimasa Shimizu, Shoichi Fukui, Ayako Nishino, Yoshiro Horai, Yasuko Hirai, Shin-ya Kawashiri, Naoki Iwamoto, Toshiyuki Aramaki, Mami Tamai, Hideki Nakamura, Kazuo Yamamoto, Norio Abiru, Tomoki Origuchi, Yukitaka Ueki, Atsushi KawakamiCitation: Clinical Immunology, 187, pp.50-57; 201
Thrombospondin-1は関節リウマチにおいて滑膜組織及び血漿レベルで過剰発現しており、 滑膜線維芽細胞ではtransforming growth factor-β1により誘導される
No full textObjective: To investigate the role of thrombospondin 1 (TSP-1) in RA. Methods: Expression of TSP-1 in synovial tissues was determined by immunohistochemistry. Expression of TSP-1 in rheumatoid fibroblast-like synovial cells (FLS) was investigated by quantitative real-time PCR and ELISA. Correlations among the plasma TSP-1 and other variables in patients with RA were examined. Results: Expression of TSP-1 was increased in rheumatoid synovial tissues. Transforming growth factor-β1 (TGF-β1) clearly increased TSP-1 expression in FLS on both mRNA and protein levels. Changes in plasma TSP-1 were associated with those in 28-joint Disease Activity Score-erythrocyte sedimentation rate and plasma TGF-β1. Conclusion: TSP-1 might be critically involved in the disease process of RA through the TGF-β1/TSP-1 axis.長崎大学学位論文 学位記番号:博(医歯薬)甲第768号 学位授与年月日:平成27年3月20日Author: Takahisa Suzuki, Naoki Iwamoto, Satoshi Yamasaki, Ayako Nishino, Yoshikazu Nakashima, Yoshiro Horai, Shin-ya Kawashiri, Kunihiro Ichinose, Kazuhiko Arima, Mami Tamai, Hideki Nakamura, Tomoki Origuchi, Chikara Miyamoto, Makoto Osaki, Kaname Ohyama, Naotaka Kuroda, Atsushi KawakamiCitation: The Journal of Rheumatology, 42(6), pp.943-947; 201
Las horas y la Puertas del Olimpo (Homero E 749-751 = Θ 393-395)
No full textThe author argues that the image of the Horai as guardians of the doors of the Olymp in E 749-51 = θ 393-95 is presumably a rest of an old theogony. The mention of Uranos and Olymp in the same verse shows some interpretation problems, that is why the author assumes that Homer has adapted this passage from an older source, in which Uranos was still considered a god and not a place
Las horas y las Puertas del Olimpo (Homero "E" 749-751= "Th" 393-395)
No full textThe author argues that the image of the Horai as guardians of the doors of the Olymp in E 749-51 = θ 393-95 is presumably a rest of an old theogony. The mention of Uranos and Olymp in the same verse shows some interpretation problems, that is why the author assumes that Homer has adapted this passage from an older source, in which Uranos was still considered a god and not a place
Current Diagnosis and Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Review Including a Comparison of Characteristics in Europe and Japan
No full textAnti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a disease entity characterized by systemic vasculitis positive for ANCAs, which often leads to severe organ damage such as diffuse bronchoalveolar hemorrhage and rapidly progressive glomerulonephritis. It is known that the incidence and characteristics of AAV vary depending on region, and differences in the peak age of onset, the ratio of positive rates of MPO-ANCA to PR3-ANCA, and occurrence rates of GPA and MPA may have resulted in different approaches to clinical practice. It may also be necessary to modify therapeutic strategies according to ethnic factors. Avacopan is a therapeutic option recently recommended for the management of AAV; however, the rate of severe liver injuries associated with avacopan was reported to be relatively high in the Japanese population. In this review, we introduce current globally recognized knowledge on the diagnosis and treatment of AAV, including a comparison of patient characteristics and clinical practice between Europe and Japan obtained from the recent literature
A Review of the Impact of Sjögren’s Syndrome and/or the Presence of Anti-Ro/SS-A Antibodies on Therapeutic Strategies for Rheumatoid Arthritis
No full textRheumatoid arthritis (RA) is an immune-mediated disease characterized by polyarthritis that affects the small joints of the bilateral upper and lower extremities. RA shares several common clinical symptoms with Sjögren’s syndrome (SS), another rheumatic disease caused by the lymphocytic infiltration of exocrine glands, with dry eye and dry mouth being the two most common symptoms. Anti-Ro/SS-A antibodies, a diagnostic biomarker of SS, are positive in patients with RA at a certain rate. The coexistence of SS and/or positivity for anti-Ro/SS-A antibodies in patients with RA influences disease activity and the effectiveness of several classes of disease-modifying antirheumatic drugs (DMARDs). Furthermore, RA, SS, and certain DMARDs, including methotrexate, are associated with the onset of lymphoproliferative disorders (LPD). In contrast, several biological DMARDs, such as tocilizumab and rituximab, are plausible options without the risk of LPD relapse. Considering the results of the studies introduced in this article, RA with SS and/or positivity for anti-Ro/SS-A antibodies could be considered a phenotype different from isolated RA from the perspective of refractoriness to DMARD therapy and LPD risk. Hence, rheumatologists should observe caution when choosing DMARDs. Further studies are needed to establish the appropriate treatment for patients with RA, SS, and/or the presence of anti-Ro/SS-A antibodies
Recent Advances in Pathogenesis, Diagnostic Imaging, and Treatment of Sjögren’s Syndrome
No full textIt is our pleasure to present the Special Issue “Diagnosis and Treatment of Sjögren’s Syndrome” to the readers of the Journal of Clinical Medicine [...
A Review of the Current Clinical Aspects of Sjögren’s Disease: Geographical Difference, Classification/Diagnostic Criteria, Recent Advancements in Diagnostic Methods, and Molecular Targeted Therapy
No full textSjögren’s Disease (SjD) is an autoimmune disorder characterized by sicca symptoms arising from impaired salivary and lacrimal gland function and accompanying extraglandular involvement. SjD is recognized as an illness of female dominance for which the 2002 American–European Consensus Group Classification Criteria and the American College of Rheumatology/European Alliance of Associations for Rheumatology 2016 classification criteria are utilized for inclusion in clinical trials, and treatment recommendations from countries belonging to the American College of Rheumatology or the European Alliance of Associations for Rheumatology are globally recognized. It is presumed that there are geographical differences among female sufferers, and unique diagnostic criteria and recommendations are used in clinical practice in Japan. In addition to the items included in the classification criteria, several methods to measure saliva secretion, serum biomarkers, and artificial intelligence tools have recently been reported to be useful for the assessment of SjD. While symptomatic therapies including tear drops, artificial saliva, and muscarinic agonists are still the mainstay for treating SjD, several kinds of molecular targeted drugs, such as biological drugs and Janus kinase inhibitors, that are expected to improve the prognosis of SjD have been tested in recent clinical trials
Anti-transcription Intermediary Factor1γ-antibody-positive Dermatomyositis Complicated by Dysphagia
No full textModulation of Apoptosis by Cytotoxic Mediators and Cell-Survival Molecules in Sjögren’s Syndrome
No full textThe pathogenesis of Sjögren’s syndrome (SS) involves multiple factors including genetic background, cell death, and exocrine dysfunction. We here discuss apoptotic control in exocrine glands in SS by showing various pro- and anti-apoptotic pathways. Although the membrane-bound and soluble form of the Fas/Fas ligand system is a leading player with activation of the death domain and caspase 8/3 cleavage, the role of soluble Fas/FasL (including its polymorphism) in apoptosis is controversial. The tumor necrosis factor related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of salivary gland epithelial cells (SGECs) involves a mitochondrial pathway that includes caspase 9 cleavage. The involvement of innate immunity cells such as toll-like receptors (TLRs) has been investigated; TLR2-4 and TLR7-9 are associated with the induction of inflammation in exocrine glands of SS patients. TLR3 has the potential to induce the apoptosis of SS patients’ SGECs. Linkage of epidermal growth factor (EGF) was shown in exocrine glands in SS, and it inhibited the Fas/FasL system with the help of cell-survival factors. TLR3 has dual actions to cause inflammation as well as apoptosis, which are inhibited by EGF. In conclusion, apoptosis in exocrine glands of SS patients is tightly controlled by balance of pro-apoptotic signals and growth factor
- …
